SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · IEX Real-Time Price · USD
2.130
+0.040 (1.91%)
At close: Jul 19, 2024, 4:30 PM
2.210
+0.080 (3.76%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
SCYNEXIS Revenue
SCYNEXIS had revenue of $140.39M in the twelve months ending March 31, 2024, with 2,436.77% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $1.37M with 21.50% year-over-year growth. In the year 2023, SCYNEXIS had annual revenue of $140.14M with 2,652.72% growth.
Revenue (ttm)
$140.39M
Revenue Growth
+2,436.77%
P/S Ratio
0.57
Revenue / Employee
$4,840,862
Employees
29
Market Cap
80.47M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 140.14M | 135.05M | 2,652.72% |
Dec 31, 2022 | 5.09M | -8.07M | -61.32% |
Dec 31, 2021 | 13.16M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 121.00K | -136.00K | -52.92% |
Dec 31, 2018 | 257.00K | - | - |
Dec 31, 2017 | 257.00K | - | - |
Dec 31, 2016 | 257.00K | - | - |
Dec 31, 2015 | 257.00K | -999.00K | -79.54% |
Dec 31, 2014 | 1.26M | -15.60M | -92.55% |
Dec 31, 2013 | 16.86M | 20.00K | 0.12% |
Dec 31, 2012 | 16.84M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Protalix BioTherapeutics | 59.65M |
DBV Technologies | 14.94M |
Ikena Oncology | 3.85M |
Serina Therapeutics | 3.15M |
Nutriband | 2.02M |
Chimerix | 41.00K |
SCYX News
- 2 months ago - SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID) - GlobeNewsWire
- 3 months ago - SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - GlobeNewsWire
- 4 months ago - SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference - GlobeNewsWire
- 7 months ago - FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm - Accesswire
- 7 months ago - Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - PRNewsWire
- 7 months ago - SCYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - PRNewsWire